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Effects of sodium orthovanadate on whole kidney and single
nephron function. The renal effects of sodium vanadate
(Na3VO4), an inhibitor of sodium-potassium-ATPase recently
shown to be a potent diuretic, were studied by using clearance
and micropuncture techniques in nondiuretic anesthetized rats.
Administration of 1.0 zmole of sodium vanadate (high dose) in-
creased urine flow rate (V) from 9.8 1.4 to 17.5 4.0 p.1/mm
(mean SEM, P < 0.025), U5aV from 1.73 0.36 to 3.05 0.65
jzEq/min (P < 0.025), and FENa from0.67 0.15 to 1.24 0.28%(P < 0.025). No significant changes in GFR or RPF were ob-
served. Late proximal tubular-fluid-to-plasma (F/P) inulin de-
creased from 2.28 0.19 to a minimum value of 1.38 0.06 (P <
0.025). Absolute water reabsorption decreased from 15.8 3.5
to 6.5 1.7 nI/mm (P < 0.025) and fractional water reabsorption
from 52.0 4.4 to 26.5 4.1% (P < 0.025). The injection of 0.5
p.mole of sodium vanadate (low dose) resulted in no significant
changes in V. Late proximal F/P inulin decreased, however,
from 2.37 0.14 to a minimum value of 1.59 0.12 (P < 0.025).
SNGFR remained unchanged, as did GFR and RPF. UNaV in-
creased from 1.41 0.35 to 2.25 0.35 p.Eq/min (P < 0.025),
and FENa rose from 0.64 0.16 to 0.91 0.15% (P < 0.025). The
decrease in F/P inulin was observed in all but one animal, even in
the absence of a diuretic response. The amount of fluid remaining
in the lumen of the late proximal tubule was virtually the same in
both low- and high-dose animals (18.9 3.0 and 19.5 3.4 nl/
mm, respectively). We conclude that sodium vanadate causes a
decrease in superficial proximal tubule fluid and salt reabsorp-
tion. Inasmuch as the low dose does not result necessarily in a
diuretic response, an increase in fluid reabsorption distal to the
late proximal tubule must take place.
Effets de l'orthovanadate de sodium sur La fonction du rein en-
tier et des néphrons individuels. Les effets rénaux du vanadate de
sodium (Na3VO4), un inhibiteur de Ia sodium-potassium-ATPase
dont ii a éte montre récemment qu'il est un diurétique puissant,
out été étudiés au moyen des techniques de clearance et de mi-
croponction chez des rats anesthésiés non diuretiques.
L'administration de 1,0 p.mole de vanadate de sodium (dose é-
levee) a augmenté le debit urinaire (V) de 9,8 1,4 a 17,5 4,0
p.1/mm (moyenne SEM, P <0,025), UNaV de 1,73 0,36 . 3,05
0,65 p.Eq/min (P < 0,025) et FENa de 0,67 0,15 a 1,24
0,28% (P < 0,025). II n'a pas été observe de modification signifi-
cative de GFR ou RPF. Le rapport inuline tubulaire/inuline
plasmatique (F/P inulin) a Ia fin du tube proximal a diminué de
2,28 0,19 a une valeur minimale de 1,38 0,06 (P < 0,025). La
reabsorption absolue d'eau a diminué de 15,8 3,5 a 6,5 1,7
nI/mm (P < 0,025) et Ia reabsorption fractionnelle d'eau de 52,0
4,4 a 26,5 4,1% (P < 0,025). L'injection de 0,5 p.moles de
vanadate de sodium (dose faible) n'a pas determine de modifica-
tion significative de V. Le rapport inuline tubulaire/inuline
plasmatique ala fin du proximal, cependant, a diminué de 2,37
0,14 a une valeur minimale de 1,59 0,12 (P < 0,025). SNGFR
est resté inchangé, de même que GFR et RPF. UNaV a augmente
de 1,41 0,35 a 2,25 0,35 p.Eq/min (P < 0,025) et FENa a
augmenté de 0,64 0,16 a 0,91 0,15% (P < 0,025). La diminu-
tion de F/P inuline a été observée chez tous les animaux saufun,
même en l'absence de réponse diuretique. La quantité de liquide
present dans la lumière a Ia fin du tube proximal ëtait pratique-
ment Ia méme que Ia dose administrée ait été faible ou forte (18,9
3,0 et 19,5 3,4 nI/mm, respectivement). Nous concluons que
vanadate de sodium determine une diminution de Ia reabsorption
d'eau et de sel par les tubes proximaux superficiels. Du fait que
Ia dose faible n'entraine pas toujours une réponse diuretique une
augmentation de Ia reabsorption d'eau en aval de La fin du tube
proximal doit exister.
Sodium orthovanadate (Na3VO4), a potent inhib-
itor of sodium-potassium-ATPase [1, 2], has recent-
ly been reported to be a potent diuretic and natriu-
retic substance [3]. Although a proximal tubule ef-
fect was suggested, no information on whole kidney
and single nephron function is available after so-
dium vanadate administration.
The present studies were undertaken to deter-
mine the effects of sodium vanadate on renal func-
tion by clearance and micropuncture techniques.
Identification of the site(s) of action of vanadate
may be important not only to characterize its diuret-
ic action, but also to provide insight into a new pos-
sible mechanism of regulation of renal sodium ex-
cretion.
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It was found that sodium vanadate produces an
inhibition of superficial proximal fluid reabsorption
in the absence of significant changes in renal plasma
flow, GFR, and single nephron GFR. Tubule seg-
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ments beyond the late proximal tubule increased
their reabsorption rate and blunted the diuretic re-
sponse when a low dose of vanadate (0.5 tmole)
was administered.
Methods
Observations are reported on 51 female Sprague-
Dawley rats of 180 to 340 g of body wt. The animals
were fasted overnight, and water was allowed ad
lib. They were anesthetized with a priming i.p. dose
of 50 mg/kg of body wt of sodium pentobarbital
(Abbott Laboratories, N. Chicago, Illinois). Intra-
venous doses of the drug were used as needed
throughout the experiment. A tracheostomy was
performed, the animals were placed on a thermo-
regulated table, and the body temperature was
maintained at 37 0.5°C. PE-50 and PE-lO cath-
eters (Clay Adams, Parsippany, New Jersey) were
placed in the right external jugular vein and two PE-
10 catheters into the right femoral vein for the in-
fusion of isotonic solution (145 m sodium chlo-
ride, 5 mrvl potassium chloride) at a rate of 2.2 mI/hr
and for other infusions. The right femoral artery
was cannulated for blood collections. Arterial blood
pressure (BP) was monitored throughout the experi-
ment from the left femoral artery by means of a
mercury manometer. The left kidney was prepared
for micropuncture by the method described by
Gottschalk and Mylle [4]. The renal capsule was left
intact. The exposed kidney was covered with agar,
except the anterior surface, and bathed in mineral
oil. Both ureters were cannulated near the kidney
with PE-50 catheters for urine collections. Appro-
priate amounts of '4C-inulin (New England Nuclear,
Boston, Massachusetts) or nonradioactive inulin
(Fisher Scientific Co., Fair Lawn, New Jersey) and
PAH (Merck, Sharp & Dohme, West Point, Penn-
sylvania) were added to the isotonic solution for de-
termination of GFR and renal plasma flow (RPF).
Blood samples were collected at the midpoint of
each period from the right femoral artery for the
measurement of plasma sodium and potassium, he-
matocrit, inulin, and PAH; and from the renal vein
by direct puncture with a 27-gauge needle for the
determination of PAH extraction. After 1 hour of
equilibration, whole kidney and single nephron
measurements were performed during two 30-mm
control periods. Fresh solutions of sodium vanadate
were prepared in 0.25 ml of saline. Experiments
were divided into five groups as follows: Group 1 (N
= 19): Control. After obtaining two control periods,
a volume of 0.25 ml of saline was injected, via the
femoral vein, and the study was continued for two
additional experimental periods. Group 2 (N = 9):
After the control periods, a low dose (0.5 mo1e) of
sodium vanadate (Fisher Scientific Co., Fair Lawn,
New Jersey) was injected via the femoral vein, and
clearance studies and micropuncture were per-
formed during two 30-mm periods. Group 3 (N = 7):
The protocol was identical to that of group 2 except
that a higher dose of sodium vanadate (1.0 mole)
was injected. Group 4 (N = 8): The 0.5-mole dose
was injected, and after two 30-mm experimental pe-
riods it was followed by the higher dose (1.0
mole), and the same measurements were repeated
for two additional 30-mm experimental periods.
Because there were no significant differences be-
tween the results obtained from group 4 after 0.5
j.mole, as compared with group 2, or between the
results obtained after the 1.0-j.mole dose in groups
3 and 4, the results with low and high dose from
group 4 were incorporated into groups 2 and 3, re-
spectively. Group 5 (N = 8): In preliminary experi-
ments, a dose of 1.5 mole, which has been report-
ed to be diuretic [3], was used in eight animals re-
ceiving isotonic solution at 5.5 ml/hr. This dose
produced, in three of the rats, apnea and circulatory
arrest. Whole kidney measurements were obtained
in the animals that survived and the results are re-
ported.
Whole kidney function. Measurements of V,
UNaV, UKV, FENa, GFR, and RPF were performed
during two 30-mm control periods and after van-
adate injection for another two 30-mm periods. In
some animals, the diuretic peak was determined by
measuring urine flow at 1- to 5-mm intervals by
means of a calibrated capillary tube.
Micropuncture. Only animals having a mean
blood pressure of 90 mm Hg or higher and a late
proximal tubular transit time of less than 11 sec
were used (N = 28 experiments). Late proximal
convolutions were selected by injection of small
amounts of nigrosin dye into proximal convolutions
with small tipped pipettes (external tip diameter,
approximately 5 m) and identifying the last loops
on the surface. In some animals, late proximal con-
volutions were identified with the use of a 5% buf-
fered solution of FD&C green dye (Keystone Ani-
line & Chemical Co., Chicago, Illinois). The collec-
tions were performed with sharpened micropipettes
having external tip diameters of 8 to 10 m. A col-
umn of stained mineral oil, of a length equivalent to
3 to 4 tubule diameters, was introduced into the lu-
men, and fluid was collected at a rate such that the
oil block was maintained stationary, just distal to
the pipette tip, while avoiding changes in tubule di-
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Fig. 1. A Effect of i.v. administration of 1.5 zmo1es of sodium vanadate on urine flow rate in a representative rat. The sodium chloride
(145 mM) and potassium chloride (5 mM) solution infusion rate was 5.5 mI/hr during control measurements, and it was increased to
corr,ensate for urinary volume losses. B Effect of iv. administration of 0.5 and 1.0 pmole of sodium vanadate on urine flow rate. Lack
of response to 0.5 mole of sodium vanadate was followed by a 10-fold increase in urine volume after 1.0 mole. Note the different scale
compared to A. Infusion rate was 2.2 ml/hr, with no adjustment for losses.
ameter. Collections were obtained from the same or
from new convolutions during two 30-mm control
and experimental periods. Micropuncture after ad-
ministration of vanadate was started when the green
dye transit times and blood pressures were not dif-
ferent from those measured under control condi-
tions.
Calculations.
SNGFR = (F/P)1 x V1 (ni/mm)
where SNGFR is single nephron filtration rate,
(F/P)1 is the fluid-to-plasma inulin concentration ra-
tio, and V1 is tubular fluid flow rate.
Q = SNGFR — V1 (nl/min) (2)
where Q, is the absolute reabsorption of filtrate in
proximal tubule.
Q% = (1 — (P/F)1) x 100%
where Q% is the fractional reabsorption in the
proximal tubule. GFR was measured by the clear-
ance of inulin, and RPF was determined from the
clearance and extraction of PAH.
Analytical methods. Nonradioactive inulin con-
centrations in plasma and urine were determined by
the anthrone method [5]. PAH concentration was
determined by the method of Smith et al [6]. '4C-
inulin was measured in a liquid scintillation spec-
trometer (Packard Tricarb, Packard Instrument Co.,
Downer Grove, Illinois). Sodium and potassium
concentrations were measured with a flame pho-
tometer (model 143, Instrumentation Laboratory
Inc., Watertown, Massachusetts). Statistical analy-
ses were carried out by Student's I test for paired or
nonpaired groups according to the experimental de-
sign. Results are referred to as "significant" when
11)
theirP values are < 0.025. All results are expressed
as the means SEM.
Results
The injection of 1.5 moles of sodium vanadate
resulted in hypotension (mean blood pressure fell to
less than 60 mm Hg in five out of eight animals) ac-
companied by a transient cessation in urine output
(of approximately 5 mm's duration). Three animals
had cardiorespiratory arrest. Clearances from the
1.5-j.mole group are reported in Table 1D. The
mean increase in V ranged from 1.4- to 9.0-fold in
30 mm (see Fig. 1A). The unstable hemodynamic
conditions made this group unsuitable for micro-
puncture. Doses of 1.0 and 0.5 /Lmole were used in
the remaining experiments to prevent or minimize
circulatory responses. Sodium vanadate at a dose of
1.0 mole produced only transient hypotension and
renal vasoconstriction (1 to 2 mm) if injected slow-
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ly. Decreases of mean blood pressure of more than
10 mm Hg were observed in 9 out of 15 animals
(range, 12 to 95 mm Hg; mean decrease, 40 mm
Hg). The 0.5-tmole dose resulted in a decrease in
blood pressure of more than 10 mm Hg in 8 out of 16
animals (mean decrease, 42 11 mm Hg), lasting
no more than 1 mm. The blood pressure recovered
in both groups to a value not significantly different
from the control (116 4 and 112 4 mm Hg
control and recovery, respectively).
Sodium concentration in plasma remained unal-
tered in all experimental groups during all periods
(control, 150 2 mEq/liter; 0.5 mole dose, 148 2
mEq/liter; and 1.0-mole dose, 149 1 mEq/liter).
During the E1 period (from the time of injection to
30 mm), there were no differences in PK between
control (4.1 0.3 mEq/liter) and experimental
groups (4.2 0.2 mEq/liter for 0.5 mole; and 4.0
0.2 mEq/liter for 1.0 mo1e). During the E2 period
(from 30 to 60 mm after injection), animals of the
0.5-smole series exhibited a significant decrease (P
< 0.025) of P to 3.6 0.2 mEq/liter. This value
was no different from the values of the control and
the 1.0-jsmole series (3.8 0.1 and 3.9 0.2 mEqI
liter, respectively). Hematocrit values were 46 2;
48 1; and 48 1% for control, 0.5-mole, and
1.0-j.mole series, respectively, at the beginning of
the experiment. No significant change took place.
Whole kidney function
The results of whole kidney function are reported
in Table 1.
Group 1: Control. There were no changes in any
of the parameters studied.
Group 2. Sodium vanadate, 0.5 tmo1e, did not
result in a significant overall change in V (see Fig.
1B), even though in 5 out of 16 animals an increase
of at least 50% was observed. There were signifi-
cant increases, however, in UNaV and FENa. On the
other hand, GFR, RPF, and UKV remained un-
changed.
Group 3. The injection of 1.0 tmole resulted in a
significant increase in V, UNaV, and FENa. UKV,
GFR, and RPF remained unchanged. A character-
istic diuretic response is shown in Figure lB. The
onset of the diuresis occurred between 5 to 15 mm
after the injection. Some delayed responses (diure-
sis starting at 30 mm) were recorded, however.
Micropuncture studies
Table 2 depicts the mean results of micropunc-
ture experiments for the control group and for the
groups injected with vanadate.
Group I (N = 81 punctures). Injection of the ve-
hicle alone did not result in changes of (FIP)1,
SNGFR, or Q and Q%. (FIP)1 values of this con-
trol series are shown in Fig. 2A.
Table 1. Effect of sodium vanadate and vehicle injection (control) on whole kidney functiona
GFR RPF
V UNaV FENa UKV mI/mm 100 g mI/mm 100 g
pi/min p.Eq/min % p.Eq/min body wt body wt
A. Control
C 8.3 0.9 0.60 0.20 0.28 0.11 1.52 0.08 0.72 0.06 2.01 0.15
E1 8.7 1.0 0.65 0.23 0.26 0.10 1.65 0.23 0.73 0.05 2.05 0.20
E2 8.0 0.8 0.66 0.19 0.32 0.10 1.55 0.13 0.73 0.07 2.23 0.14
N (16) (16) (16) (4) (16) (9)
B. 0.5 j.mole
C 11.7 2.2 1.41 0.35 0.64 0.16 1.71 0.21 0.71 0.05 2.85 0.47
E1 13.2 2.5 2.08 0.58 1.06 0.44 1.73 0.13 0.73 0.05 2.80 0.32
E2 12.1 1.3 2.25 0.35* 0.91 0.15* 1.74 0.14 0.73 0.06 3.04 0.43
N (16) (13) (12) (11) (15) (10)
C. 1.0moIe
C 9.8 1.4 1.73 0.36 0.67 0.15 1.79 0.14 0.74 0.05 3.02 0.25
E1 17.5 40* 3.15 0.86 1.39 0.41* 1.79 0.13 0.80 0.05 3.23 0.32
E2 13.5 2.3* 3.05 0.65* 1.24 0.28* 1.75 0.14 0.81 0.08 3.22 0.59
N (15) (14) (14) (14) (14) (13)
D. 1.5 *moles
C 15.7 4.2 1.14 0.45 0.62 0.24 1.30 0.25 0.60 0.03 2.44 0.36
E1 32.4 7.0* 4.18 1.57 1.73 0.55* 1.71 0.09 0.82 0.23 2.48 0.10
E2 82.4 46.4 4.78 1.27* 2.81 Ø79* 1.68 0.17 0.60 0.13 2.74 0.36
N (6) (4) (4) (4) (4) (2)
Values are means SEM. N is the number of experiments in each series. C is the control period (mean of two 30-mm periods). E1 and
E2 refer to the periods of 30 mm each, after injection of 0.25 ml of saline (A) or sodium vanadate (B, C, and D). Infusion rate for control
and 0.5 and 1.0 mo1e was 2.2 ml/hr; for 1.5 mo1es, the infusion was at 5.5 mI/hr. Asterisk (*) denotes the value to be significantly
different from control (P < 0.025 or better).
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Table 2. Effect of sodium vanadate on single nephron functions
SNGFR Qj Q
(F/P) inulin nI/mm ni/mm %
A. Control (N = 13)
C 2.40 0.15 33.8 2.4 19.0 1.4 56.9 2.4
E1 2.40 0.13 33.4 1.7 19.3 1.4 57.2 1.9
E2 2.43 0.10 32.4 2.6 18.6 1.4 57.9 1.7
B. 0.5 moles (N 8)
.
C 2.37 0.14 34.3 4.5 18.0 2.3 54.7 2.3
E1 1.66 0.12* 29.7 3.0 10.8 1.7* 36.5 4.8*
E2 2.18 0.27 26.5 4.0 13.5 3.4 50.3 6.2
(FIP) inulin peak 1.59 0.12* 29.1 4.5 10.3 2.3* 34.4 5.0*
C. 1.Oiimole(N= 7)
C 2.28 0.19 29.9 5.2 15.8 3.5 52.0 4.4
E1 1.74 0.15* 32.1 4.6 12.6 2.1 39.3 5.0*
E2 1.74 0.19* 28.4 4.7 10.8 2.5 38.3 5.2*
(F/P)inulin peak 1.38 0.06* 23.4 3.8 6.5 1.7* 26.5 4.1*
Values are means SEM. N is the number of experiments. Asterisks denote P < 0.025, comparison with control values. C is the
control period. E1 and E2 are the 30-mm periods following the injection of vehicle (A) or sodium vanadate (B and C). (FtP) inulin was
measured at the last accessible loop of proximal tubules.
Group 2 (N = 38 punctures). The injection of 0.5
mole of sodium vanadate resulted in a 30% de-
crease in (F/P)1 as shown in Table 2B (experimental
period E1). During the following period (E2), the ef-
fect disappeared and (F/P)1 rose to values not
different from the control ones. SNGFR did not
change significantly. Q decreased by 40% and
Q% was reduced by 33% (Table 2). The maximum
effect of vanadate was taken to be the peak de-
crease of(F/P)1 in each animal. It was 1.59 0.12,
as shown in Table 2. Values of (F/P)1 plotted as a
function of time after injection of vanadate to the
nearest 10 mm are depicted in Fig. 3A. As seen,
the decrease in (FIP)1 was statistically significant
for 20 mm after injection of vanadate. Such a de-
crease was observed in all but one experiment (see
Fig. 2B), regardless of the presence or absence of a
diuretic response.
Group 3 (N = 38 punctures). The 1.0-tmole in-
jection resulted in significant decreases in (F/P)111
during both experimental periods (E1 and E2, see
Table 2C and Fig. 2C). The lowest value of the
(F/P)111 was 1.38 0.06, significantly reduced as com-
pared with control but not different from the lowest
(F/P)1 obtained with the low dose. Q was signifi-
cantly reduced by 59%. No significant changes in
SNGFR were observed. The time course of (F/P)1
values (to the nearest 10 mm) after injection is
Fig. 2. EJfrct of sodium vanadate on late proximal (F/P) inulin. A Control experiments. (F/P) inulin values were obtained in control
conditions (C) and after injection of vehicle (0.25 ml of saline solution). Mean values are shown of collections until 30 mm (E1) and from
30 to 60 mirl (E2) of the injection (N = 13). B Mean values before (C) and after injection of 0.5 izmole of sodium vanadate. Asterisks
denote P < 0.025 (N 8). C Mean values of(F/P) inulin during control period (C) and after injection of 1.0 mole sodium vanadate.
Asterisks denote P < 0.025 (N 7).
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Fig. 3. A Time course of the effect of 0.5 tunole of sodium van-
adate on late proximal (FIP) inulin (mean SEM, 43 micro-
punctures). This includes one experiment in which samples were
obtained only after 30 mm. In animals with transient hypoten-
sion, measurements were performed 5 to 10 mm after recovery of
transit time and blood pressure. Asterisks denote P < 0.025.
B Time course of the effect of 1.0 emole of sodium vanadate
on late proximal (FtP) inulin (mean SEM, 44 micropunctures).
This includes one experiment in which samples were obtained
only after 30 mm. Asterisks denote P < 0.025.
shown in Fig. 3B. Significant decreases were ob-
served from 10 to 50 mm after injection. Delivery of
fluid to distal segments was not different between
the 0.5- and 1.0-lLmole doses (18.9 3.0 and 19.5
3.4 nI/mm, respectively).
Discussion
The studies reported here were designed to estab-
lish the site(s) of action of vanadate in the nephron.
From the magnitude of the diuretic and natriuretic
effects of vanadate, Balfour, Grantham, and Glynn
[3] predicted inhibition of fluid reabsorption at the
proximal tubule. Our studies demonstrate that the
superficial proximal tubule is in fact a site of action
of vanadate.
The diuretic response observed in our experi-
ments with a 1.5-ILmole dose was smaller than the
one reported by Balfour et a! [3]. It should be noted,
however, that the conditions of the two series of
experiments were different. To measure differences
in proximal tubule fluid reabsorption, we preferred
to study hydropenic animals in which the changes
of (F/P)1 might be more easy to detect. In addition,
our animals were anesthetized and had had surgery,
and both conditions can diminish V [7, 8]. The indi-
vidual diuretic responses were quite variable within
this group of animals, a fact that could relate to the
transient, but severe, hemodynamic changes that
developed after the injection.
Effects of vanadate on whole kidney function.
The whole kidney function measurements demon-
strate the absence of changes in GFR or RPF at all
doses, suggesting that a tubular mechanism is re-
sponsible for the diuretic and natriuretic responses.
Because the effect of vanadate (at the doses used) is
short-lasting, we considered it important to shorten
the clearance periods in order to minimize the pos-
sibility of ignoring brief changes of GFR and/or RPF
masked by rapid functional recovery. In several an-
imals, subjected to different doses of vanadate,
clearances were measured in 10-mm periods for the
duration of the experiments. No significant changes
in GFR and RPF were observed in this group.
Effects of vanadate on single nephron function.
In all but one of the animals injected with 0.5 to 1.0
/Lmole of sodium vanadate, (F/P)10 at the late proxi-
mal tubule was decreased. It is unlikely that the
short period of hypotension and renal vasoconstric-
tion observed in approximately half of the animals
played a significant role in the reduction of late
proximal (FIP)1. Nevertheless, because glomerular
hemodynamics were not studied, small changes,
undetectable by SNGFR and whole kidney RPF
measurements, cannot be completely ruled out.
The observation of a reduction of reabsorption by
superficial proximal tubules with low vanadate
dose, with no concomitant diuretic response, in-
dicates that segments beyond the late proximal tu-
bule increased their rate of reabsorption, compen-
sating for the increased load. As it is well known
from microperfusion and micropuncture studies in
the rat [9—11], increased delivery of sodium to the
loop of Henle and more distal tubule segments
leads, through unclear mechanisms, to an increase
in absolute reabsorption of sodium.
A diuretic and natriuretic response was observed
in animals treated with the high vanadate dose. The
mean peak value of (F/P)1 was lower in the high-
dose group as compared with the low-dose group;
however, there was no statistical difference be-
IC=Ca-
3'
2
3
2
Na3VO
4 10 umole
308 Higashi and Bello-Reuss
tween these values. The experimental design (bolus
injection) makes it difficult to rule out the possibility
that under steady-state conditions the proximal ef-
fect of the high dose of vanadate may be greater
than that of the low dose. Therefore, we cannot ex-
clude the hypothesis that the effect of vanadate is
restricted to the proximal tubule. It is necessary to
consider, in addition, the following possibilities: (a)
inhibition of reabsorption at some site(s) beyond the
late proximal tubule and (b) heterogeneity in the ef-
fects of vanadate on superficial and deep nephrons.
On the basis of the demonstrated effects of van-
adate on sodium-potassium-ATPase in different
systems, including renal tissue [12], one would ex-
pect, in principle, inhibitory effects of vanadate all
along the renal tubule. Variations of the effects at
different sites of the nephron could be explained,
however, by differences in the penetration into the
tubular cells, different rates of transformation of
vanadate to vanadyl [13], presence of cate-
cholamines [14], intrinsic differences between the
sodium pumps at these segments, and other, as yet
unidentified, mechanisms.
Even though it has been demonstrated that van-
adate stimulates adenylate cyclase in some systems
[15], recent observations have shown that it does
not produce an increase in urinary excretion of cy-
clicAMP [16].
In summary, our results show that vanadate, in-
jected at doses of 1.0 smole or greater, causes a
diuretic and natriuretic response in the anesthetized
rat. This effect occurs with no change in UKV. The
main site of action of vanadate is the proximal con-
voluted tubule, where absolute and fractional fluid
reabsorption are reduced. Because at low doses (0.5
mole) reabsorption by superficial proximal tubules
is diminished, but no diuretic response is observed,
we conclude that under these circumstances com-
pensation at a site(s) distal to the late proximal tu-
bule occurs. High dose (1.0 mole) produces a diu-
retic response associated with a prolonged reduc-
tion in late proximal (F/P)1. The differences
between the effects of low and high dose might be
due to further reduction of proximal tubule reab-
sorption, undepicted by the bolus injection pro-
tocol, to an effect on a more distal site or to hetero-
geneity of the response of deep nephrons.
Acknowledgments
This investigation was supported by Grant RHT-
F40501-03 I from the Jewish Hospital of St. Louis
and in part by NIH Grant AM09976-15C13. We are
indebted to Dr. C. W. Gottschalk for his comments
on a preliminary version of the manuscript. We also
wish to acknowledge the technical assistance of R.
White and the secretarial assistance of H. Odle. Dr.
Y. Higashi is a Research Fellow of the Jewish Hos-
pital of St. Louis.
Reprint request to Dr. Elsa Bello-Reuss, Jewish Hospital of
St. Louis, 216 South Kingshighway, St. Louis, Missouri 63/10,
USA
References
1. JOSEPHSON L, CANTLEY LC JR: Isolation of a potent
(Na-K)ATPase inhibitor from striated muscle. Biochemistry
16:4572—4578, 1977
2. CANTLEY LC JR, JOSEPHSON L, WARNER R, YANAGISAWA
M, LECHENE C, GUIDOTTI G: Vanadate is a potent (Na,K)-
ATPase inhibitor found in ATP derived from muscle. J Biol
Chem 252:7421—7423, 1977
3. BALFOUR WE, GRANTHAM JJ, GLYNN TM: Vanadate-stimu-
lated natriuresis. Nature 275:768, 1978
4. GOTTSCHALK CW, MYLLE M: Micropuncture study of pres-
sures in proximal tubules and peritubular capillaries of the
rat kidney and their relation to ureteral and renal venous
pressures. Am J Physiol 185:430—439, 1956
5. FUi J, KACZMARCZYK J, KRUTTGEN C-D: Eine einfache
colorimetrische Methode zur Inulinbestimmung für Nieren-
clearance-untersuchungen bei Stoffwechselgesunden und
Diabetickern. K/in Wochenschr 33:729—730, 1955
6. SMITH HW, FINKELSTEIN N, ALIMINOSA L, CRAWFORD B,
GRABER M: The renal clearances of substituted hippuric
acid derivatives and other aromatic acids in dog and man.
J C/in invest 24:388—404, 1945
7. KNIGHT TF, SANSOM S, HAWK L, FRANKFURT Si, WEIN-
MAN EJ: The effects of anesthesia on the excretion of an
isotonic saline load in the rat. Pfluegers Arch 373:139—
143, 1978
8. MADDOX DA, PRICE DC, RECTOR FC JR: Effects of surgery
on plasma volume and salt and water excretion in rats.
Am J Physiol 233:F600-F606, 1977
9. MORGAN T, BERLINER RW: A study of continuous micro-
perfusion of water and electrolyte movements in the loop
of Henle and distal tubule of the rat. Nephron 6:388-405,
1969
10. DAVIDMAN M, ALEXANDER E, LALONE R, LEVINSKY N:
Nephron function during volume expansion in the rat. Am J
Physiol 223:188—193, 1972
11. STEIN iH, OSGOOD RW, BOONJARERN S, FERRIS TF: A
comparison of the segmental analysis of sodium reabsorp-
tion during Ringer's and hyperoncotic albumin infusion in
the rat. J C/in Invest 52:2313—2323, 1973
12. GRANTHAM ii, GLYNN IM: Renal Na,-K-ATPase: Determi-
nants of inhibition by vanadium. Am J Physiol 236:F530-
F535, 1979
13. CANTLEY LC JR, AISEN P: The fate of cytoplasmic van-
adium: Implications on (Na,K)-ATPase inhibition. J Biol
Chem 254:1781-1784, 1979
14. CANTLEY LC JR, FERGUSON JH, JUSTIN K: Norepinephrine
complexes and reduces vanadium (V) to reverse vanadate
inhibition of the (Na,K)-ATPase. J Am Chem Soc 100:5210-
5212, 1978
15. SCHWABE U, PUCHSTEIN C, HANNEMANN H, SÔCHTIG E:
Activation of adenylate cyclase by vanadate. Nature
277:143—145, 1979
16. DAY H, HEINZ A, LUKERT B, GRANTHAM J: Determinants
of the renal response to intravenous vanadate (abst). Kid-
ney hit 16:851, 1979
